quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 11, 2026

Bird Reports 2025 Fourth Quarter Results; $11 Billion Combined Backlog and Pending Backlog

View original at globenewswire.com
Bird Reports 2025 Fourth Quarter Results; $11 Billion Combined Backlog and Pending Backlog MISSISSAUGA, Ontario, March 11, 2026 (GLOBE NEWSWIRE) -- “In 2025, Bird successfully navigated near‑term revenue timing shifts while continuing to progress margins and strengthen the business…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bird remains strongly positioned for Canada's long-duration nation-building investment cycle, including large-scale capital investment energy projects such as LNG and nuclear, as well as infrastructure renewal across defence, healthcare, transportation and trade

    60% confidence

  • The sole project for the customer with impaired receivables is substantially complete and no further costs are expected to be incurred

    60% confidence

  • Bird's risk-balanced combined backlog reflects higher margins than a year ago, giving confidence in achieving growth and further profitability enhancement in 2026 and 2027

    60% confidence

  • Strong demand across key strategic sectors drove record combined backlog with accretive embedded margins, providing historic levels of forward visibility into revenue and earnings growth

    60% confidence

  • With record liquidity and a strong balance sheet, Bird enters 2026 with flexibility, visibility, and momentum

    60% confidence

  • Bird successfully navigated near-term revenue timing shifts while continuing to progress margins and strengthen the business in 2025

    60% confidence

  • Revenue for Q4 2025 was lower than 2024 driven by ongoing impact of previously disclosed delays in start of certain contracted projects

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Bird Reports 2025 Fourth Quarter Results; $11 Billion Combined Backlog and Pending Backlog — Source | Via News | pt.VIA.NEWS